Amolyt Pharma SAS announced that it has received ?138 million in Series C round of financing co-led by new investors, Sofinnova Crossover I, a fund managed by Sofinnova Partners SAS for ?18 million and Intermediate Capital Group plc on January 6, 2023. The transaction included participation from new investors Tekla Capital Management LLC and CTI Life Sciences, returning investors Novo Ventures, a fund managed by Novo Holdings A/S, , Kurma Partners SA, EQT Life Sciences, InnoBio 2, FCPI, a fund managed by Bpifrance Investissement SAS, , Pontifax Venture Capital, OrbiMed Advisors LLC, Mass General Brigham Ventures, LLC, Credit Agricole Creation, Crédit Agricole Régions Investissement SAS and Turenne Santé and other investors Andera Partners Sectoral Asset Management Inc. and ATEM Capital. The company issued common shares in the transaction.

Cédric Moreau from Sofinnova Partners SAS and Toby Sykes from Intermediate Capital Group plc will join the organization as the board of directors.